Low-Dose 0.01% Atropine Eye Drops vs Placebo forMyopia Control A Randomized Clinical Trial
3 institutional releases
Published in JAMA Ophthalmology · View the paper (DOI)
A randomized clinical trial found that low-dose atropine eye drops did not slow myopia progression or axial elongation in US school-age children. The results suggest that atropine, 0.01%, eye drops are not effective for controlling myopia in this population.
Coverage from 3 institutions
- Low-dose atropine eye drops vs placebo for myopia control JAMA Network · Jul 13, 2023 · first to report
- Low-dose atropine eyedrops no better than placebo for slowing myopia progression NIH/National Eye Institute · Jul 13, 2023
- VUMC participates in national study to test eye drops for nearsightedness Vanderbilt University Medical Center · Aug 1, 2023